Septic shock resuscitation in the first hour

Current Opinion in Critical Care

Volumn 23, Issue 6, 2017, Pages 561-566

  Simpson, Nicholas ^a   Lamontagne, Francois ^b,c   Shankar Hari, Manu ^d,e  

^a BARWON HEALTH   (Australia)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^c UNIVERSITY OF SHERBROOKE   (Canada)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

microcirculation; resuscitation; sepsis; septic shock

Indexed keywords

ANTIBIOTIC AGENT; CATECHOLAMINE; HYPERTENSIVE FACTOR; VASOACTIVE AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; CENTRAL VENOUS PRESSURE; CLINICAL EXAMINATION; CLINICAL OUTCOME; CRITICALLY ILL PATIENT; FLUID BALANCE; FLUID THERAPY; HUMAN; HYPOTENSION; INOTROPISM; MICROCIRCULATION; MORTALITY; PERIPHERAL CIRCULATION; PRACTICE GUIDELINE; RESUSCITATION; REVIEW; SEPTIC SHOCK; BLOOD PRESSURE MEASUREMENT; EARLY DIAGNOSIS; EARLY GOAL-DIRECTED THERAPY; INTENSIVE CARE; PATHOPHYSIOLOGY; PROCEDURES; SEPSIS; TIME TO TREATMENT;

ANTI-BACTERIAL AGENTS; BLOOD PRESSURE DETERMINATION; CRITICAL CARE; EARLY DIAGNOSIS; EARLY GOAL-DIRECTED THERAPY; FLUID THERAPY; HUMANS; HYPOTENSION; PRACTICE GUIDELINES AS TOPIC; RESUSCITATION; SEPSIS; SHOCK, SEPTIC; TIME-TO-TREATMENT;

EID: 85033781203     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0000000000000460     Document Type: Review

References (46)

1. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315:801-810.
2. Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315:762-774.
3. Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315:775-787.
4. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013; 369:840-851.
5. Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017; 43:304-377.
6. Dünser MW, Takala J, Brunauer A, Bakker J. Re-Thinking resuscitation: leaving blood pressure cosmetics behind and moving forward to permissive hypotension and a tissue perfusion-based approach. Crit Care 2013; 17:326.
7. van Beest P, Lont M, Holman N, et al. Central venous-Arterial pCO2 difference as a tool in resuscitation of septic patients. Intensive Care Med 2013; 39:1034-1039.
8. Mekontso-Dessap A, Castelain V, Anguel N, et al. Combination of venoarterial PCO2 difference with arteriovenous O2 content difference to detect anaerobic metabolism in patients. Intensive Care Med 2002; 28:272-277.
9. Hotchkiss RS, Moldawer LL, Opal SM, et al. Sepsis and septic shock. Nat Rev Dis Primers 2016; 2:16045.
10. Ince C, Mik EG. Microcirculatory and mitochondrial hypoxia in sepsis, shock, and resuscitation. J Appl Physiol (1985) 2016; 120:226-235.
11. Moore JP, Dyson A, Singer M, Fraser J. Microcirculatory dysfunction and resuscitation: why, when, and how. Br J Anaesth 2015; 115:366-375.
12. Matkovich SJ, Al Khiami B, Efimov IR, et al. Widespread down-regulation of cardiac mitochondrial and sarcomeric genes in patients with sepsis. Crit Care Med 2017; 45:407-414.
13. Takasu O, Gaut JP, Watanabe E, et al. Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am J Respir Crit Care Med 2013; 187:509-517.
14. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368-1377.
15. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637.
16. Angus DC, Barnato AE, Bell D, et al. A systematic review and meta-Analysis of early goal-directed therapy for septic shock: The ARISE, ProCESS and ProMISe investigators. Intensive Care Med 2015; 41:1549-1560.
17. Investigators P, Rowan KM, Angus DC, et al. Early, goal-directed therapy for septic shock: A patient-level meta-Analysis. N Engl J Med 2017; 376:2223-2234.
18. Jones AE, Shapiro NI, Trzeciak S, et al., Emergency Medicine Shock Research Network (EMShockNet) Investigators. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: A randomized clinical trial. JAMA 2010; 303:739-746.
19. Jansen TC, van Bommel J, Schoonderbeek FJ, et al., LACTATE Study Group. Early lactate-guided therapy in intensive care unit patients: A multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med 2010; 182:752-761.
20. Puskarich MA, Trzeciak S, Shapiro NI, et al., Emergency Medicine Shock Research Network (EMSHOCKNET). Prognostic value and agreement of achieving lactate clearance or central venous oxygen saturation goals during early sepsis resuscitation. Acad Emerg Med 2012; 19:252-258.
21. Vincent JL, Quintairos ES, Couto L Jr, Taccone FS. The value of blood lactate kinetics in critically ill patients: A systematic review. Crit Care 2016; 20:257.
22. Adeva-Andany M, Lopez-Ojen M, Funcasta-Calderon R, et al. Comprehensive review on lactate metabolism in human health. Mitochondrion 2014; 17:76-100.
23. Mallat J, Lemyze M, Tronchon L, et al. Use of venous-To-Arterial carbon dioxide tension difference to guide resuscitation therapy in septic shock. World J Crit Care Med 2016; 5:47-56.
24. Marik PE, Khangoora V, Rivera R, et al. Vitamin C, and thiamine for the treatment of severe sepsis and septic shock: A retrospective before-After study. Chest 2017; 151:1229-1238.
25. Byrne L, Van Haren F. Fluid resuscitation in human sepsis: Time to rewrite history? Ann Intensive Care 2017; 7:4.
26. Marik PE, Linde-Zwirble WT, Bittner EA, et al. Fluid administration in severe sepsis and septic shock, patterns and outcomes: An analysis of a large national database. Intensive Care Med 2017; 43:625-632.
27. Seethala RR, Hou PC, Aisiku IP, et al. Early risk factors and the role of fluid administration in developing acute respiratory distress syndrome in septic patients. Ann Intensive Care 2017; 7:11.
28. Patel A, Pieper K, Myburgh JA, et al. Reanalysis of the crystalloid versus hydroxyethyl starch trial (CHEST). N Engl J Med 2017; 377:298-300.
29. Caironi P, Tognoni G, Masson S, et al., ALBIOS Study Investigators. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014; 370:1412-1421.
30. Sakr Y, Rubatto Birri PN, Kotfis K, et al., Intensive Care Over Nations Investigators. Higher fluid balance increases the risk of death from sepsis: results from a large international audit. Crit Care Med 2017; 45:386-394.
31. Seymour CW, Gesten F, Prescott HC, et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 2017; 376: 2235-2244.
32. Maitland K, Kiguli S, Opoka RO, et al., FEAST Trial Group. Mortality after fluid bolus in African children with severe infection. N Engl J Med 2011; 364:2483-2495.
33. Hjortrup PB, Haase N, Bundgaard H, et al., CLASSIC Trial Group; Scandinavian Critical Care Trials Group. Restricting volumes of resuscitation fluid in adults with septic shock after initial management: The CLASSIC randomised, parallel-group, multicentre feasibility trial. Intensive Care Med 2016; 42:1695-1705.
34. Rameau A, de With E, Boerma EC. Passive leg raise testing effectively reduces fluid administration in septic shock after correction of non-compliance to test results. Ann Intensive Care 2017; 7:2.
35. Dubin A, Pozo MO, Casabella CA, et al. Increasing arterial blood pressure with norepinephrine does not improve microcirculatory blood flow: A prospective study. Crit Care 2009; 13:R92.
36. Lamontagne F, Marshall JC, Adhikari NK. Permissive hypotension during shock resuscitation: equipoise in all patients? Intensive Care Med 2017.
37. Russell JA, Lee T, Singer J, et al., Vasopressin and septic shock trial (VASST) group. The septic shock 3.0 definition and trials: A vasopressin and septic shock trial experience. Crit Care Med 2017; 45:940-948.
38. Gordon AC, Mason AJ, Thirunavukkarasu N, et al., VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The VANISH Randomized Clinical Trial. JAMA 2016; 316:509-518.
39. Russell JA, Walley KR, Singer J, et al., VASST Investigators. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887.
40. Vail EA, Gershengorn HB, Hua M, et al. Epidemiology of vasopressin use for adults with septic shock. Ann Am Thorac Soc 2016; 13:1760-1767.
41. Correa TD, Takala J, Jakob SM. Angiotensin II in septic shock. Crit Care 2015; 19:98.
42. Khanna A, English SW, Wang XS, et al., ATHOS-3 Investigators. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 2017; 377:419-430.
43. Hajjej Z, Meddeb B, Sellami W, et al. Effects of levosimendan on cellular metabolic alterations in patients with septic shock: A randomized controlled pilot study. Shock 2017; 48:307-312.
44. Gordon AC, Perkins GD, Singer M, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 2016; 375:1638-1648.
45. Landoni G, Lomivorotov VV, Alvaro G, et al., CHEETAH Study Group. Levosimendan for hemodynamic support after cardiac surgery. N Engl J Med 2017; 376:2021-2031.
46. Mehta RH, Leimberger JD, van Diepen S, et al., LEVO-CTS Investigators. Levosimendan in patients with left ventricular dysfunction undergoing cardiac surgery. N Engl J Med 2017; 376:2032-2042.